TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience

Covid19 Clinical Trial

Official title:

TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04730323
• Other study ID #: IRB# FMH-05-2020-IRB-75
• Status: Completed
• Phase: Phase 4
• Start date: May 12, 2020
• Est. completion date: June 12, 2020

Study information

• Verified date: January 2021
• Source: FMH College of Medicine and Dentistry
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Investigators conducted this study to see the effectiveness of Tocilizumab in COVID-19 participants who were in cytokine release syndrome and there was also a control group who received steroids(RECOVERY TRIAL wasn't published or available at that time) this study was conducted in the early days of 1st wave of COVID in our country Pakistan so it was need of the day to develop some national guidelines on the basis of multiple studies' results from Pakistan.

Description:

Objectives: To analyze the effectiveness of Tocilizumab in moderate to severe Covid-19 participants on the basis of predefined assessment criteria.

Study Settings: Single center, Fatima Memorial Hospital, Lahore.

Study Design: Quasi experimental.

Duration of Study: From 12th May, 2020 to 12th July, 2020.

Participants & Methods: Sample size and technique: Sample size was 93; 33 participants were kept in experimental group, given Tocilizumab, 8mg/kg intravenously or 162 mg subcutaneously and rest of the 60 participants were given corticosteroids, methylprednisolone 80 mg/day. Consecutive sampling.

Failure of therapy was labeled when participants were intubated or died, and the endpoints were failure-free survival which was the primary endpoint and overall survival secondary at the time of discharge.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 93
• Est. completion date: June 12, 2020
• Est. primary completion date: June 12, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years to 85 Years

Eligibility

• Inclusion Criteria:

• All patients diagnosed with COVID-19 infection with positive reverse transcriptase RT-PCR test, willing to participate in this study or PCR negative patients with clinically COVID-19 Pneumonia in cytokine storm as evidenced by raised inflammatory markers with typical radiological changes

• Patients of both genders were included

• Patients having an age of > 65 years with proven Cardiomyopathy, Coronary artery disease, chronic lung disease, Immunosuppressed or organ transplant End-stage renal disease on history & examination and medical records and having any 1 out of 4 Fever 0f

• =39 C

• Hypotension or drop in mean arterial pressure of > 10mmHg

• Progressive Hypoxemia requiring > 5 liters of oxygen

• Sustained Respiratory rate >30/min with any 2 laboratory parameters out of 3 are present D-dimers = 1000 ng/ml C-reactive protein CRP = 100mg/L Ferritin = 600ng/ml

• Patients having low risk or no comorbidities and having an age of <65 years with having any 3 out of 4 Fever 0f

• =39 C

• Hypotension or drop in mean arterial pressure of > 10mmHg

• Progressive Hypoxemia requiring > 5 liters of oxygen

• Sustained Respiratory rate >30/min With any 2 laboratory parameters out of 3 are present D-dimers = 1000 ng/ml C-reactive protein CRP = 100mg/L Ferritin = 600ng/ml

• Moderate severe or severe COVID 19 features

1. Shortness of breath oxygen saturation <93% on room air

2. Progressive Hypoxemia requiring > 5 liters of oxygen

3. Respiratory rate >30/min

4. The partial pressure of arterial oxygen to fraction of inspired oxygen ratio<300

5. Lung infiltrates on Chest x-ray CXR >50% within 24 to 48 hrs

6. Respiratory failure

• Exclusion Criteria:

• Known severe allergic reactions to Tocilizumab or any other monoclonal antibody

• Pregnancy or breastfeeding

• Absolute Neutrophil Count(ANC) < 1000

• Alanine aminotransferase(ALT) or aspartate aminotransferase (AST) > 5 times upper normal limit

• Platelet count of < 50,000

• Bowel diverticulitis or bowel perforation

• Patients having Acute pancreatitis

Related Conditions & MeSH terms

• Covid19

Intervention

Drug:
• Tocilizumab
Participants received an initial dose calculated as per the body weight (8mg/kg) maximum 800mg/dose) over 1 hour, followed by up to three additional doses if required as per the response after the first dose with 8 hours intervals. Predefined Parameters of disease severity were assessed 12 to 24 hourly. Injection Paracetamol 1g was administered before infusion. The response of the participants after Tocilizumab administration was recorded based on clinical parameters (Oxygen requirement, Fever, Need for invasive positive pressure ventilation), biochemical parameters (D-dimers, C-reactive protein (CRP), Ferritin, Lactate dehydrogenase (LDH) levels), Chest X-ray findings, and Repeated PCR test for COVID-19. Any side effects noted after administration of TOCILIZUMAB were recorded. Any side effects noted after administration of TCZ/ Corticosteroid were recorded.

Locations

Country	Name	City	State
Pakistan	Fatima Memorial Hospital College of Medicine & Dentistry	Lahore	Punjab

Sponsors (1)

Lead Sponsor	Collaborator
FMH College of Medicine and Dentistry

Country where clinical trial is conducted

Pakistan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Decreased Mortality in Participants	investigators tried to find out that whether there is decreased mortality in expermiental and active Comparator group or not	30 days
Primary	Hospital & ICU stay in days	investigators tried to find out that whether there is decreased hospital and ICU stay in experimental group & active Comparator	14 days